Strides Pharma Science’s arm gets USFDA approval for Colchicine Tablets

11 Mar 2022 Evaluate

Strides Pharma Science’s (Strides) step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Colchicine Tablets USP, 0.6 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Colcrys Tablets, 0.6 mg, of Takeda Pharmaceuticals U.S.A., Inc. (Takeda).

According to IQVIA MAT January 2022 data, the US market for Colchicine Tablets USP, 0.6 mg is approximately around $ 85 Mn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 271 cumulative ANDA filings with USFDA of which 245 ANDAs have been approved and 26 are pending approval.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

793.60 -2.60 (-0.33%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×